CN114195883A - 针对抗原ny-eso-1的mhci和mhcii表位的癌症组合t细胞受体基因疗法 - Google Patents

针对抗原ny-eso-1的mhci和mhcii表位的癌症组合t细胞受体基因疗法 Download PDF

Info

Publication number
CN114195883A
CN114195883A CN202111497633.4A CN202111497633A CN114195883A CN 114195883 A CN114195883 A CN 114195883A CN 202111497633 A CN202111497633 A CN 202111497633A CN 114195883 A CN114195883 A CN 114195883A
Authority
CN
China
Prior art keywords
leu
ser
thr
val
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111497633.4A
Other languages
English (en)
Chinese (zh)
Inventor
T.布兰肯斯坦
L.庞塞特
陈晓婧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Original Assignee
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft filed Critical Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Publication of CN114195883A publication Critical patent/CN114195883A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278Knock-in vertebrates, e.g. humanised vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202111497633.4A 2015-03-13 2016-03-11 针对抗原ny-eso-1的mhci和mhcii表位的癌症组合t细胞受体基因疗法 Pending CN114195883A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP15159001.5 2015-03-13
EP15159001.5A EP3067366A1 (en) 2015-03-13 2015-03-13 Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1
CN201680015622.9A CN107428816B (zh) 2015-03-13 2016-03-11 针对肿瘤抗原ny-eso-1的mhc i和mhc ii-限制表位的癌症的组合t细胞受体基因疗法
PCT/EP2016/055242 WO2016146505A1 (en) 2015-03-13 2016-03-11 Combined t cell receptor gene therapy of cancer against mhc i and mhc ii-restricted epitopes of the tumor antigen ny-eso-1

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680015622.9A Division CN107428816B (zh) 2015-03-13 2016-03-11 针对肿瘤抗原ny-eso-1的mhc i和mhc ii-限制表位的癌症的组合t细胞受体基因疗法

Publications (1)

Publication Number Publication Date
CN114195883A true CN114195883A (zh) 2022-03-18

Family

ID=52669528

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202111497633.4A Pending CN114195883A (zh) 2015-03-13 2016-03-11 针对抗原ny-eso-1的mhci和mhcii表位的癌症组合t细胞受体基因疗法
CN201680015622.9A Active CN107428816B (zh) 2015-03-13 2016-03-11 针对肿瘤抗原ny-eso-1的mhc i和mhc ii-限制表位的癌症的组合t细胞受体基因疗法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680015622.9A Active CN107428816B (zh) 2015-03-13 2016-03-11 针对肿瘤抗原ny-eso-1的mhc i和mhc ii-限制表位的癌症的组合t细胞受体基因疗法

Country Status (13)

Country Link
US (1) US10781243B2 (https=)
EP (3) EP3067366A1 (https=)
JP (2) JP6998211B2 (https=)
CN (2) CN114195883A (https=)
AU (1) AU2016232441B2 (https=)
CA (1) CA2974955A1 (https=)
DK (1) DK3268385T3 (https=)
ES (1) ES2784315T3 (https=)
HU (1) HUE049444T2 (https=)
PL (1) PL3268385T3 (https=)
PT (1) PT3268385T (https=)
SI (1) SI3268385T1 (https=)
WO (1) WO2016146505A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
AU2014343379B2 (en) 2013-11-04 2019-02-14 Uti Limited Partnership Methods and compositions for sustained immunotherapy
EP3291832B1 (en) 2015-05-06 2025-09-03 UTI Limited Partnership Nanoparticle compositions for sustained therapy
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
EP3354658A1 (en) * 2017-01-25 2018-08-01 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Novel t cell receptors and immune therapy using the same for the treatment of cancer and infectious diseases
US11236145B2 (en) 2017-03-23 2022-02-01 Immatics Biotechnologies Gmbh T cell receptors and immune therapy using the same against PRAME positive cancers
WO2018185564A2 (en) * 2017-04-07 2018-10-11 Uti Limited Partnership Assay to measure the potency of receptor-ligand interactions in nanomedicines
CN109837245A (zh) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 一种tcr敲除的靶向ny-eso-1的t细胞受体基因修饰t细胞及其制备方法和应用
CA3083748A1 (en) 2017-11-29 2019-06-06 Uti Limited Partnership Methods of treating autoimmune disease
TWI822726B (zh) * 2018-02-26 2023-11-21 德商梅迪基因免疫治療公司 Nyeso t細胞受體
CN110856751B (zh) 2018-08-24 2024-12-03 杭州康万达医药科技有限公司 包含核酸及tcr修饰的免疫细胞的治疗剂及其应用
EP3935175A4 (en) 2019-03-04 2023-01-04 University Health Network T-LYMPHOCYTE RECEPTORS AND METHODS OF USE THEREOF
EP3760217A1 (en) 2019-07-01 2021-01-06 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Cd5 specific t cell receptor cell or gene therapy
US20220273714A1 (en) * 2019-07-19 2022-09-01 The Regents Of The University Of California T-cell receptors and methods of use thereof
CN112390875B (zh) * 2019-08-16 2023-01-24 香雪生命科学技术(广东)有限公司 一种识别afp的高亲和力t细胞受体
CN113512124A (zh) * 2020-04-10 2021-10-19 香雪生命科学技术(广东)有限公司 一种识别hpv16的高亲和力tcr
CN112501269B (zh) * 2020-12-15 2022-02-18 清华大学 一种快速鉴定高亲和力tcr抗原交叉反应活性的方法
CN114121142B (zh) * 2021-09-02 2023-10-31 四川大学华西医院 一种新型基因修饰增强型ny-eso-1特异型tcr-t模型构建方法及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000060055A1 (en) * 1999-04-01 2000-10-12 The Brigham And Women's Hospital, Inc. Modified dendritic cells and uses therefor
WO2001055393A2 (en) * 2000-01-28 2001-08-02 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1
ES2389251T3 (es) * 2000-12-19 2012-10-24 Altor Bioscience Corporation Animales transgénicos que comprenden un sistema inmunitario humanizado
AU2003217384A1 (en) * 2002-02-13 2003-09-04 Ludwig Institute For Cancer Research Isolated peptides which bind to hla molecules and uses thereof
GB0411123D0 (en) * 2004-05-19 2004-06-23 Avidex Ltd High-affinity NY-ESO T cell receptors
WO2006031221A1 (en) * 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
KR101773690B1 (ko) * 2007-03-05 2017-08-31 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 항원 특이적 t 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용
CN101381402B (zh) * 2008-10-20 2011-06-01 中国人民解放军第三军医大学 Ny-eso-1肿瘤抗原模拟表位及其应用
HRP20171164T1 (hr) 2010-09-20 2017-10-20 Biontech Cell & Gene Therapies Gmbh Antigen-specifični t stanični receptori i t stanični epitopi
EP2852613B1 (en) * 2012-05-22 2019-01-23 The United States of America, as represented by The Secretary, Department of Health and Human Services Murine anti-ny-eso-1 t cell receptors
CA2899679C (en) 2013-01-29 2023-03-21 Max-Delbruck-Centrum Fur Molekulare Medizin (Mdc) Berlin-Buch High avidity antigen recognizing constructs
RU2578009C2 (ru) * 2013-05-08 2016-03-20 Закрытое акционерное общество "ЕВРОГЕН" Способ идентификации нативных пар фрагментов днк или рнк, присутствующих в одних и тех же живых клетках
US11203783B2 (en) * 2013-11-21 2021-12-21 Repertoire Genesis Incorporation T cell receptor and B cell receptor repertoire analysis system, and use of same in treatment and diagnosis

Also Published As

Publication number Publication date
AU2016232441A1 (en) 2017-08-10
AU2016232441B2 (en) 2020-08-27
EP3268385A1 (en) 2018-01-17
EP3666793A3 (en) 2020-07-29
SI3268385T1 (sl) 2020-07-31
WO2016146505A1 (en) 2016-09-22
EP3268385B1 (en) 2020-01-08
CN107428816B (zh) 2022-01-14
CN107428816A (zh) 2017-12-01
CA2974955A1 (en) 2016-09-22
PT3268385T (pt) 2020-04-08
DK3268385T3 (da) 2020-04-06
ES2784315T3 (es) 2020-09-24
EP3666793A2 (en) 2020-06-17
EP3067366A1 (en) 2016-09-14
JP2021151249A (ja) 2021-09-30
HK1247212A1 (en) 2018-09-21
US10781243B2 (en) 2020-09-22
JP6998211B2 (ja) 2022-02-04
PL3268385T3 (pl) 2020-06-29
JP2018509163A (ja) 2018-04-05
HUE049444T2 (hu) 2020-09-28
US20180057560A1 (en) 2018-03-01

Similar Documents

Publication Publication Date Title
AU2016232441B2 (en) Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1
US12338272B2 (en) High avidity antigen recognizing constructs
AU2017205637B2 (en) Compositions and libraries comprising recombinant T-cell receptors and methods of using recombinant T-cell receptors
WO2000031239A1 (en) Immune cells having predefined biological specificity, comprising chimeric t cell receptor
CN113195526B (zh) 针对过继性t细胞疗法中的突变myd88l265p蛋白表位的特异性t细胞受体
CN114302962B (zh) 特异性针对来源于ebv抗原的tcr构建体
CN109251243B (zh) 一种识别sage1抗原的t细胞受体及编码该受体的核酸
CN118909085A (zh) 识别wt1抗原短肽的t细胞受体(tcr)、多价tcr的复合物、药物组合物及用途
EP4328239A1 (en) Immunotherapeutics based on magea1-derived epitopes
HK1247212B (en) Combined t cell receptor gene therapy of cancer against mhc i and mhc ii-restricted epitopes of the tumor antigen ny-eso-1
EP2803363B1 (en) The antigen CYBA-72Y/B15 and uses thereof
HK1218551B (en) High avidity binding molecules recognizing mage-a1
CN110938642A (zh) 靶向CD123-BBz-IL1RN的嵌合抗原受体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination